Copeptin as a Biomarker of Atherosclerosis in Type 1 Diabetic Patients

Soha M. Abd El Dayem; Ahmed A. Battah; Abo El Magd El Bohy; Rasha Nazih Yousef; Ahmed Talaat

doi:10.3889/oamjms.2019.643

Authors

Soha M. Abd El Dayem Pediatrics Department, National Research Centre, Cairo, Egypt
Ahmed A. Battah Critical Care Department, Cairo University, Cairo, Egypt
Abo El Magd El Bohy Radiology Department, Cairo University, Cairo, Egypt
Rasha Nazih Yousef Clinical Pathology Department, National Research Centre, Cairo, Egypt
Ahmed Talaat Pediatrics Department, National Research Centre, Cairo, Egypt

DOI:

https://doi.org/10.3889/oamjms.2019.643

Keywords:

Copeptin, CIMT, type 1 diabetes

Abstract

AIM: To evaluate copeptin as an early marker of atherosclerosis in adolescent type 1 diabetics.

METHODS: Sixty-two type 1 diabetic patients and 50 healthy volunteers were enrolled in the study. Serum copeptin, glycosylated haemoglobin (HbA1c), lipid profile, oxidised low-density lipoprotein (OxLDL), urinary albumin/creatinine ratio, carotid intimal medial thickness (cIMT), aortic intimal medial thickness (aIMT) and resistivity index were assessed for all participant in the study.

RESULTS: HbA1, albumin/creatinine ratio, lipid profile, OxlDL, copeptin, cIMT and aIMT were significantly higher in diabetic patients. Copeptin was higher in patients with positive cIMT and aIMT. Copeptin correlated with cIMT and aIMT. Stepwise multiple regression analysis found that copeptin correlated with aIMT. ROC curve showed that copeptin had 100 % specificity with aIMT and cIMT and 95.2 and 60,7 sensitivity with aIMT and cIMT respectively.

CONCLUSION: Copeptin can be used as a marker for early detection of atherosclerosis of type 1 diabetic patients.